Exscientia Investor Relations Material

Exscientia plc is a pharmatech company leveraging artificial intelligence (AI) in the discovery, design, and development of drugs. The company employs a patient-first AI approach across various stages of drug development, including precision target identification, design, experimentation, and medicine optimization. It aims to accelerate the process of bringing new, effective treatments to patients with a focus on precision oncology and a broader range of therapeutic areas through partnered pipelines. The company is headquartered in Oxford, United Kingdom, and its shares are listed on the Nasdaq.